{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:35:15Z","timestamp":1787027715903,"version":"build-2736575974"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgical intervention remains necessary. Methods: We prospectively analyzed the treatment outcomes of 51 patients with locally advanced, nonmetastatic GISTs treated with neoadjuvant imatinib followed by surgery. The optimal duration was defined as the timepoint when there was a &lt;10% change in the treatment response or a size decrease of less than 5 mm between two consecutive computed tomography scans. Results: Primary tumors were located in the stomach (23\/51; 45%), followed by the rectum (17\/51; 33%), ileum\/jejunum (9\/51; 18%), and esophagus (2\/51; 4%). The median maximal shrinkage time was 6.1 months, beyond which further treatment may not be beneficial. However, the maximal shrinkage time was 4.3 months for the stomach, 8.6 months for the small bowel and 6.9 months for the rectum. The R0 tumor resection rate in 27 patients after neoadjuvant imatinib and surgery was 81.5%, and 70.4% of resection procedures succeeded in organ preservation. However, 10 of 51 patients (19.6%) had complications following neoadjuvant imatinib use (six from imatinib and four from surgery). Conclusion: Our analysis supports treating GIST patients with neoadjuvant imatinib, which demonstrated favorable long-term results of combined therapy. However, careful monitoring of complications is necessary. The optimal duration of neoadjuvant imatinib use before surgical intervention is, on average, 6.1 months.<\/jats:p>","DOI":"10.3390\/cancers11030424","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T05:03:12Z","timestamp":1553662992000},"page":"424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1514-3015","authenticated-orcid":false,"given":"Shang-Yu","family":"Wang","sequence":"first","affiliation":[{"name":"GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-8805","authenticated-orcid":false,"given":"Chiao-En","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chi","family":"Lai","sequence":"additional","affiliation":[{"name":"GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9756-3974","authenticated-orcid":false,"given":"Jen-Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yi","family":"Tsai","sequence":"additional","affiliation":[{"name":"GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tung","family":"Cheng","sequence":"additional","affiliation":[{"name":"GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Sen","family":"Yeh","sequence":"additional","affiliation":[{"name":"GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Yeh","sequence":"additional","affiliation":[{"name":"GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/path.1546","article-title":"Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity","volume":"202","author":"Wasag","year":"2004","journal-title":"J. Pathol."},{"key":"ref_2","first-page":"2305","article-title":"[Tyrosine kinase inhibitor as a targeted therapy for GIST tumors]","volume":"118","author":"Joensuu","year":"2002","journal-title":"Duodecim"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","article-title":"Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.6004\/jnccn.2012.0099","article-title":"Soft tissue sarcoma, version 2.2012: Featured updates to the NCCN guidelines","volume":"10","author":"Benjamin","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1245\/ASO.2004.09.011","article-title":"Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy","volume":"11","author":"Eisenberg","year":"2004","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00000658-199201000-00010","article-title":"Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging","volume":"215","author":"Ng","year":"1992","journal-title":"Ann. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","article-title":"NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors","volume":"8","author":"Demetri","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.21160","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132\/ACRIN 6665","volume":"99","author":"Eisenberg","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1200\/jco.2012.30.15_suppl.10031","article-title":"Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors","volume":"30","author":"Hohenberger","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1245\/s10434-008-0177-7","article-title":"A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis","volume":"16","author":"McAuliffe","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1245\/s10434-012-2559-0","article-title":"Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study","volume":"19","author":"Colombo","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1245\/s10434-012-2551-8","article-title":"Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum: A Multi-Institutional Analysis","volume":"19","author":"Johnston","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1245\/s10434-006-9047-3","article-title":"Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era","volume":"13","author":"Bonvalot","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1200\/JCO.2008.21.3330","article-title":"Absence of Progression as Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated with Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial","volume":"27","author":"Verweij","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1245\/s10434-006-9228-0","article-title":"Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by Secondary KIT Mutations","volume":"14","author":"Haller","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s00117-008-1743-5","article-title":"Volumetry of metastases from renal cell carcinoma","volume":"48","author":"Graser","year":"2008","journal-title":"Radiologe"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ejrad.2013.02.034","article-title":"Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: Comparison of RECIST, Choi and volumetric criteria","volume":"82","author":"Schramm","year":"2013","journal-title":"Eur. J. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Blesius, A., Cassier, P.A., Bertucci, F., Fayette, J., Ray-Coquard, I., Bui, B., Adenis, A., Rios, M., Cupissol, D., and Perol, D. (2011). Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-72"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00268-012-1440-4","article-title":"Gastrointestinal Stromal Tumors: Case Series of 29 Patients Defining the Role of Imatinib Prior to Surgery","volume":"36","author":"Shrikhande","year":"2012","journal-title":"World J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1245\/s10434-011-2190-5","article-title":"Phase II Trial of Neoadjuvant\/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic\/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132","volume":"19","author":"Wang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejso.2012.09.004","article-title":"Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib","volume":"39","author":"Tielen","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","article-title":"Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience","volume":"20","author":"Rutkowski","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment with Targeted Systemic Therapy Using Kinase Inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: Pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.6004\/jnccn.2016.0078","article-title":"Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Randall","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","article-title":"ESMO Guidelines Committee and EURACAN Gastrointestinal stromal tumours: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-006-9034-8","article-title":"Surgical Resection of Gastrointestinal Stromal Tumors after Treatment with Imatinib","volume":"14","author":"Andtbacka","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1245\/s10434-009-0784-y","article-title":"Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate","volume":"17","author":"Raut","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/jso.21630","article-title":"Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment","volume":"102","author":"Yeh","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijsu.2017.01.045","article-title":"Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study","volume":"39","author":"Yeh","year":"2017","journal-title":"Int. J. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/bjs.10774","article-title":"Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy","volume":"105","author":"Fairweather","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of Surgical Complications","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejso.2018.09.029","article-title":"Preoperative tyrosine kinase inhibitors risks bowel anastomotic healing in patients with advanced primary and recurrent\/metastatic gastrointestinal stromal tumors\u2014A rose has its thorns","volume":"45","author":"Lee","year":"2019","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:40:30Z","timestamp":1760186430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["cancers11030424"],"URL":"https:\/\/doi.org\/10.3390\/cancers11030424","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]}}}